Notably, VHL-based PROTAC P3 (compound 106) (Figure 21A) demonstrated significant efficacy in inducing the degradation of mutant EGFR in HCC-827 (EGFRdel19) (DC50 = 0.51 nM) and H1975 cells (EGFRL858R/T790M) (DC50 = 126.2 nM), respectively. This evidence concerns the gene EGFR and hepatocellular carcinoma.